Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy consists of allogeneic human umbilical cord-derived mesenchymal stem cells (huc-MSCs) and is being developed by Central South University for the treatment of moderate-to-severe psoriasis vulgaris. The therapy functions through potent immunomodulatory mechanisms, specifically by restoring the balance between pro-inflammatory and regulatory immune cells. It has been shown to increase the frequency of regulatory T cells (Tregs) and CD4+ memory T cells while simultaneously decreasing the population of Th17 cells and reducing systemic levels of interleukin-17 (IL-17). Administered via multiple intravenous infusions, the therapy aims to provide a safer and more durable alternative to conventional systemic treatments and biologics for patients with resistant psoriasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells (Central South University).